Form 4: SpringWorks Therapeutics Director Reports Full Disposition of Securities Following Merger with Merck KGaA

A director of SpringWorks Therapeutics, Inc. reported the complete disposition of common stock, restricted stock units, and stock options as a result of the company's merger with Merck KGaA, Darmstadt, Germany, effective July 1, 2025, at a cash consideration of $47.00 per share.

Summary

• SpringWorks Therapeutics, Inc. completed its merger with Merck KGaA, Darmstadt, Germany, effective July 1, 2025.
• As a result of the merger, SpringWorks Therapeutics, Inc. is now a wholly owned subsidiary of Merck KGaA.
• Each outstanding share of SpringWorks Therapeutics common stock was cancelled and automatically converted into the right to receive $47.00 in cash, without interest and subject to any required tax withholding.
• Reporting person Julie Hambleton, a Director, disposed of 14,155 shares of common stock, which included 10,060 shares underlying restricted stock units (RSUs).
• Julie Hambleton also disposed of stock options to purchase 14,668 shares (with an exercise price of $38.03), 15,318 shares (with an exercise price of $35.42), and 12,216 shares (with an exercise price of $44.77).
• Vested and unvested RSUs and stock options were cancelled and converted into cash-based awards (Parent Cash-Based RSU Awards and Parent Cash-Based Option Awards).
• These cash-based awards will generally vest in accordance with their original terms, with 50% of each then-unvested tranche vesting on the nine-month anniversary of the merger closing date, subject to the holder's continued employment with Parent.
• Any outstanding stock option with an exercise price greater than $47.00 was cancelled at the effective time of the merger for no consideration or payment.

Sentiment

Score: 7

Explanation: The document reports the successful completion of a merger, which typically provides a clear and expected exit for shareholders at a pre-determined price. While some out-of-the-money options were cancelled for no value, the overall outcome for shareholders and most equity award holders is a defined cash payout or continued cash-based vesting, indicating a positive and expected resolution of the transaction.

Positives

• Shareholders received a fixed cash consideration of $47.00 per share for their common stock, providing a clear exit value.
• Vested stock options and restricted stock units were converted into cash payments based on the merger consideration, realizing their value.
• Unvested RSUs and stock options were converted into cash-based awards, allowing employees to retain value from their equity incentives, with a 50% vesting acceleration on the nine-month anniversary of the merger closing, subject to continued employment.

Negatives

• Shareholders no longer hold equity in SpringWorks Therapeutics, Inc. as it has become a wholly owned subsidiary, removing future upside potential from the independent entity.
• Stock options with an exercise price greater than the $47.00 merger consideration were cancelled for no value, resulting in a loss for holders of those specific options.

Future Outlook

The document primarily reports the completion of a past event (the merger) and its immediate consequences for securities. The only forward-looking aspect is the continued vesting schedule for Parent Cash-Based RSU Awards and Parent Cash-Based Option Awards, which will generally vest in accordance with their original terms, with a 50% acceleration on the nine-month anniversary of the merger closing date, subject to the applicable holder's continued employment with Parent.

Industry Context

This merger represents a significant consolidation event within the biotechnology and pharmaceutical industry. Larger pharmaceutical companies like Merck KGaA often acquire smaller, innovative biotech firms such as SpringWorks Therapeutics to expand their drug pipelines, gain access to novel therapeutic platforms, and enhance their market position. Such acquisitions are a common strategic move for growth and intellectual property acquisition in the highly competitive life sciences sector.

Stakeholder Impact

• Shareholders: Received $47.00 cash per share for their common stock, effectively liquidating their equity stake in SpringWorks Therapeutics.
• Employees (holding RSUs/Options): Their equity awards were converted into cash-based awards, with continued vesting and potential acceleration, subject to their continued employment with the new parent company, Merck KGaA.
• Creditors: The company's financial structure and obligations are now integrated under Merck KGaA, which may impact future credit relationships, though not explicitly detailed in this filing.

Next Steps

• Continued vesting of Parent Cash-Based RSU Awards and Parent Cash-Based Option Awards for eligible employees, subject to their continued employment with Parent.
• 50% of then-unvested tranches of Parent Cash-Based RSU Awards and Parent Cash-Based Option Awards will vest on the nine-month anniversary of the merger closing date.

Key Dates

Recommendation

Keywords

SpringWorks Therapeutics, SWTX, Merck KGaA, Merger, Acquisition, SEC Form 4, Beneficial Ownership, Stock Options, Restricted Stock Units, Cash Consideration, Corporate Action, Biotechnology, Pharmaceuticals